I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
The first study of real-world efficacy and safety of Natali..:
Shahrbaf, Mohammad Amin
;
Samimi, Monireh
;
Karimi, Shahedeh
...
Trends in Immunotherapy. 8 (2024) 1 - p. 3920 , 2024
Link:
https://doi.org/10.24294/ti.v8.i1.3920
RT Journal T1
The first study of real-world efficacy and safety of Natalizumab (Tysabri®) in Iran
UL https://suche.suub.uni-bremen.de/peid=cr-10.24294_ti.v8.i1.3920&Exemplar=1&LAN=DE A1 Shahrbaf, Mohammad Amin A1 Samimi, Monireh A1 Karimi, Shahedeh A1 Salari, Mehri A1 Ghaffari, Mehran A1 Yazdanbakhsh, Sepideh A1 Najafian, Abbas A1 Vosough, Massoud A1 Nabavi, Seyed Massood PB EnPress Publisher YR 2024 SN 2573-5985 JF Trends in Immunotherapy VO 8 IS 1 SP 3920 LK http://dx.doi.org/https://doi.org/10.24294/ti.v8.i1.3920 DO https://doi.org/10.24294/ti.v8.i1.3920 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)